{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:11:37Z","timestamp":1789042297212,"version":"build-2803163510"},"reference-count":10,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1182\/blood.2026034975","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:31:58Z","timestamp":1789039918000},"page":"1365-1366","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Time will tell: 5 years of TRANSCEND"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael","family":"Dickinson","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre"},{"name":"The Royal Melbourne Hospital"},{"name":"The University of Melbourne"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2026091007314998800_bib1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.2025032270","article-title":"Five-year survival outcomes of lisocabtagene maraleucel in R\/R LBCL from the TRANSCEND NHL 001 study","volume":"148","author":"Abramson","year":"2026","journal-title":"Blood"},{"issue":"25","key":"2026091007314998800_bib2","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","article-title":"Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL)","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026091007314998800_bib3","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/bloodadvances.2020001646","article-title":"The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL","volume":"4","author":"Assouline","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"2026091007314998800_bib4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2026091007314998800_bib5","first-page":"2307","article-title":"5-year follow-up of ZUMA-1 supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"10343","key":"2026091007314998800_bib6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"2026091007314998800_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"2026091007314998800_bib8","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026091007314998800_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"issue":"21","key":"2026091007314998800_bib10","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","article-title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","volume":"9","author":"Desch\u00eanes-Simard","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/11\/1365\/2588086\/blood_bld-2026-034975-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/11\/1365\/2588086\/blood_bld-2026-034975-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:32:00Z","timestamp":1789039920000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/11\/1365\/570691\/Time-will-tell-5-years-of-TRANSCEND"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026034975","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,10]]},"published":{"date-parts":[[2026,9,10]]}}}